Lenvatinib + Pembrolizumab
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papilloma Virus
Conditions
Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease
Trial Timeline
Jul 18, 2025 → Dec 1, 2027
NCT ID
NCT04645602About Lenvatinib + Pembrolizumab
Lenvatinib + Pembrolizumab is a phase 1 stage product being developed by Eisai for Human Papilloma Virus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04645602. Target conditions include Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease.
What happened to similar drugs?
14 of 20 similar drugs in Human Papilloma Virus were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04645602 | Phase 1 | Recruiting |
| NCT04209660 | Phase 2 | Active |
| NCT03776136 | Phase 2 | Completed |
| NCT03609359 | Phase 2 | Completed |
| NCT03006887 | Phase 1 | Completed |
| NCT02501096 | Phase 1/2 | Completed |
Competing Products
20 competing products in Human Papilloma Virus